Serious adverse events · advanced gastric and oesophago‐gastric junction adenocarcinoma
Chemotherapy probably leads to higher serious adverse events compared with placebo, best supportive care (BSC) or no treatment (moderate certainty).
1 finding from 1 review
Serious adverse events · advanced gastric and oesophago‐gastric junction adenocarcinoma
Biological therapy showed no clear difference in serious adverse events compared with placebo, best supportive care (BSC) or no treatment (low certainty).
1 finding from 1 review
Serious adverse events · adult patients with non‐paracetamol (acetaminophen)‐related acute liver failure
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events · children with non‐paracetamol (acetaminophen)‐related acute liver failure
N‐acetylcysteine showed no clear difference in serious adverse events compared with placebo (low certainty).
1 finding from 1 review
Intervention not reported
Serious adverse events · adults and children with confirmed clinical and parasitological P vivax malaria
The intervention may leads to higher serious adverse events (low certainty).
1 finding from 1 review
Intervention not reported
Serious adverse events · adults and children with confirmed clinical and parasitological P vivax malaria
1 finding from 1 review
Intervention not reported
Serious adverse events · adults and children with confirmed clinical and parasitological P vivax malaria
1 finding from 1 review
Intervention not reported
Serious adverse events · adults and children with confirmed clinical and parasitological P vivax malaria
1 finding from 1 review
Serious adverse events
Knee replacement with tourniquet probably leads to higher serious adverse events compared with knee replacement without tourniquet (moderate certainty).
1 finding from 1 review
Serious adverse events · People with quiescent Crohn's disease (ileocolic resection)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events · Participants with Crohn's disease in remission
Adalimumab probably leads to lower serious adverse events compared with placebo (moderate certainty).
1 finding from 1 review
Serious adverse events
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events
1 finding from 1 review
Serious adverse events · adults with Parkinson's disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events. · adults with Parkinson's disease
It is very uncertain whether GLP‐1 receptor agonists changes serious adverse events. compared with no treatment (very low certainty).
1 finding from 1 review
Serious adverse events · patients with chronic obstructive pulmonary disease
Mepolizumab 300 mg showed no clear difference in serious adverse events compared with placebo (moderate certainty).
1 finding from 1 review
Serious adverse events · patients with chronic obstructive pulmonary disease
Mepolizumab 750 mg showed no clear difference in serious adverse events compared with placebo (low certainty).
1 finding from 1 review
Serious adverse events · patients with chronic obstructive pulmonary disease
Benralizumab 10 mg showed no clear difference in serious adverse events compared with placebo (moderate certainty).
1 finding from 1 review
Serious adverse events · patients with chronic obstructive pulmonary disease
Benralizumab 30 mg showed no clear difference in serious adverse events compared with placebo (moderate certainty).
1 finding from 1 review
Serious adverse events · patients with chronic obstructive pulmonary disease
Benralizumab 100 mg showed no clear difference in serious adverse events compared with placebo (moderate certainty).
1 finding from 1 review